[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Johannes Gutenberg University Mainz\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":389},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,45,68,102,129,157,188,212,239,262,292,313,335,365],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100453484","respiratory-variation-of-carotid-doppler-peak-velocity-cdpv-for-non-invasive-prediction-of-fluid-responsiveness-100453484",false,"NCT05185141","Respiratory Variation of Carotid Doppler Peak Velocity (CDPV) for Non-invasive Prediction of Fluid Responsiveness","Assessing Respiratory Variation of Carotid Doppler Peak Velocity (CDPV) for Non-invasive Prediction of Fluid Responsiveness During Abdominal Surgery: a Prospective Observational Trial","Inclusion Criteria:\n\n* Age 18-80 years\n* written informed consent\n* scheduled major abdominal surgery\n\nExclusion Criteria:\n\n* Age \\\u003C18 or \\>80 years\n* pregnancy\n* SIRS or sepsis\n* any kind of cardiac arrhythmia\n* known valve disease\n* known heart failure\n* any kind of known carotid stenosis\n* carotid doppler peak velocity \\>182 cm\u002Fs before baseline measurement (expected stenosis)\n* missing indication for invasive arterial blood pressure monitoring (IBP) not related to the study\n* peripheral artery disease (PAD)\n* BMI \\> 35 kg\u002Fm2\n* intraabdominal hypertension\n* ASA-PSC of 4\n* severe lung disease (e.g. COPD grade 3, fibrosis)\n* esophageal disease of any kind\n* participation in another clinical study","ALL","18 Years","80 Years",{"count":20,"type":21},84,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to assess respiratory variation of carotid doppler peak velocity (∆CDPV) for prediction of fluid responsiveness during major abdominal surgery.",[25],"Hemodynamic Instability",[27,28,29,30,31],"Fluid Responsiveness","Hemodynamic Monitoring","Carotid Doppler Peak Velocity","Pulse Pressure Variation","Fluid Challenge","RECRUITING","2026-06-09",{"date":35,"type":36},"2026-06-10","ACTUAL",{"date":38,"type":36},"2022-01-11",{"date":40,"type":21},"2026-07",{"name":42,"class":43},"Johannes Gutenberg University Mainz","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":44},"100628373","alcon-hydrus-stent-implantation---long-term-follow-up-after-8-years-100628373","NCT07460791","Alcon Hydrus Stent Implantation - Long Term Follow up After 8 Years","An Ambispective, Monocentric, Non-interventional Long-term Follow-up Trial to Evaluate the Effectiveness and Safety of the Hydrus Implant Combined With Concomitant Phacoemulsification for Lowering Intraocular Pressure (IOP) in Glaucoma Patients","Inclusion Criteria:\n\n1\\. Patient participated in one of the following trials in the clinical trial site in Mainz:\n\n1. the Ivantis, Inc. HYDRUS I trial (NCT03065036),\n2. the Ivantis, Inc. HYDRUS II trial (NCT01818115),\n3. the Ivantis, Inc. HYDRUS IV trial (NCT01539239),\n4. or in the retrospective SPECTRUM data collection. 2. Patient received either concomitant implantation of the Hydrus implant and phacoemulsification or the Hydrus implant alone or participated in the control group (phacoemusification alone) 3. Patient has a minimum follow-up period after surgery of 8 years at the study visit 4. Willingness to participate in the study, the subject's signed and dated informed consent must be submitted before the start of the study 5. Ability of subject to give consent\n\n   \\-\n\n   Exclusion Criteria:\n\n   1\\. Simultaneous participation in another interventional study or past interventions whose effect may still be ongoing (30 days)\n\n   \\-",{"count":53,"type":21},200,"The purpose of this study is to evaluate the long-term effectiveness and safety of the Hydrus implant combined with concomitant phacoemulsification for lowering intraocular pressure (IOP).Glaucoma patients often have high intraocular pressures (IOP) and need long-term IOP control to prevent loss of visual function and blindness. To date, data on the results of up to 5 years after Hydrus implantation have been published. However, to our knowledge, long-term data over a longer period of time are not yet available. The implementation of this study with a follow-up of the patients after ≥ 8 years (up to 14 years) represents the longest follow-up period to date with a cohort of up to 202 eyes in Mainz, Germany. It enables the collection of \"real world data\" ≥ 8 years after the Hydrus implantation and provides information about the current status of glaucoma and the effect of the Hydrus implant over this long period (including IOP status, IOP-lowering interventions that have taken place in the meantime, the status of the IOP-lowering medications used, ocular safety, quality of life etc.).",[56],"Glaucoma",[56,58,59],"Hydrus Stent","more than 8 years of follow up","2026-03-04",{"date":62,"type":36},"2026-03-10",{"date":64,"type":36},"2025-04-03",{"date":66,"type":21},"2026-08-31",{"name":42,"class":43},{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":76,"sex":16,"minAge":17,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":87,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":44},"100555623","differential-effects-of-in-vivo-and-virtual-exposure-therapy-in-agoraphobia-100555623","NCT06514495","Differential Effects of in Vivo and Virtual Exposure Therapy in Agoraphobia","Differential Effects of in Vivo and Virtual Exposure Therapy on the Interoception and Reactivity of Different Body Systems in Agoraphobia","VRExpo","Inclusion Criteria:\n\n* Experimental group: Diagnosis of agoraphobia with or without panic disorder\n* Clinical control group: diagnosis of social phobia\n* Control group: healthy individuals without acute or chronic mental illness\n* A depressive disorder may be present as a comorbid diagnosis in the experimental group and the clinical control group\n\nExclusion Criteria:\n\n* Other mental illnesses: Substance dependence, schizophrenia, bipolar disorder, dementia, eating disorders, PTSD, major depressive episode, personality disorder\n* Somatic diseases: Cancer, cardiovascular diseases, epilepsy, autoimmune diseases, metabolic or endocrine diseases\n* Taking psychotropic medication (except antidepressants) or medication that affects the cardiovascular system (e.g. beta-blockers), medication containing cortisone, use of creams with corticosteroids\n* Pregnancy, breastfeeding\n* Ongoing psychotherapy",true,"75 Years",{"count":79,"type":21},68,"INTERVENTIONAL",[82],"NA","Anxiety disorders, including agoraphobia, are prevalent in the German population, leading affected individuals to avoid specific places like crowds or public transport. Although cognitive-behavioral therapy with exposure is an effective treatment, many patients resort to medication rather than therapy. Virtual Reality Exposure Therapy (VRET) shows promise in easing exposure treatment with customizable scenarios. Interoception (body symptom perception) and the endocannabinoid system are explored as factors in maintaining agoraphobia. Studies investigate how therapies like exposure (both in vivo and in VR) impact these factors and treatment outcomes. Interoception, especially in panic disorder patients, plays a crucial role, with accurate heartbeat perception linked to maintaining anxiety. The endocannabinoid system, affecting various functions, is studied for its role in therapy outcomes and its modulation of the body's stress response. The study aims to understand how these systems interact in agoraphobic patients and how therapy affects their functionality.",[85,86],"Agoraphobia; Panic","Social Anxiety Disorder",[88,89,90,91,92,93],"exposure","virtual reality","interoception","cortisol","immune system","endocannabinoids","2025-08-26",{"date":96,"type":36},"2025-09-03",{"date":98,"type":36},"2025-05-01",{"date":100,"type":21},"2027-08-01",{"name":42,"class":43},{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":16,"minAge":110,"maxAge":111,"enrollmentInfo":112,"targetDuration":4,"studyType":80,"phases":114,"briefSummary":115,"conditions":116,"keywords":118,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":128},"100552899","interdisciplinary--intersectoral-telemedicine-evaluation-coordination--treatment-in-rhinemain-parkinsons-network-100552899","NCT06479083","Interdisciplinary + Intersectoral Telemedicine Evaluation, Coordination + Treatment in RhineMain+ Parkinson's Network","Interdisciplinary and Intersectoral Telemedicine Evaluation, Coordination and Treatment in the Rhine Main+ Parkinson's Network","INSPIRE-PNRM","Inclusion Criteria:\n\n* Diagnosis of primary Parkinson's syndrome (G20.-) or atypical Parkinson's syndrome (G23.-, according to the current diagnostic criteria of the Movement Disorder Society, including the criteria of at least bradykinesia and rigidity or resting tremor must be present)\n* In the care regions of Hesse and Rhineland-Palatinate\n* Ability to give consent present\n\nExclusion Criteria:\n\n\\- Severe dementia\n\n* Severe depression\n* Psychoses or other psychiatric or medical comorbidities that could affect the smooth implementation of the study protocol (e.g.\n\ntumor disease with limited life expectancy, need for dialysis, etc.)\n\n* Drug or alcohol addiction\n* Women who are pregnant or breastfeeding\n* Simultaneous participation in another interventional treatment study\n* Illiteracy or insufficient language skills","30 Years","85 Years",{"count":113,"type":21},1354,[82],"Project objective: To improve the health care of Parkinson's disease patients in the ParkinsonNetz RheinMain+.\n\nHypothesis: Through the interdisciplinary and cross- sectoral networking in a tele medical network and the coordinating function of an \"advanced practice nurse\" (APN) specially trained for Parkinson's disease, the process quality within the network is increased and the individual health status is positively influenced.",[117],"Parkinson Disease",[119],"Parkinson Disease, Advanced Practice Nurse, Telemedical, Interdisciplinary, cross-sector care networks and pathways.","2025-07-18",{"date":122,"type":36},"2025-07-23",{"date":124,"type":36},"2024-07-01",{"date":126,"type":21},"2027-01-31",{"name":42,"class":43},2,{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":136,"enrollmentInfo":137,"targetDuration":4,"studyType":80,"phases":139,"briefSummary":140,"conditions":141,"keywords":143,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":128},"100572955","effects-of-autonomic-nervous-system-modulation-by-heart-rate-variability-biofeedback-training-with-resonant-frequency-breathing-on-glucose-metabolism-in-individuals-with-prediabetes-100572955","NCT06739993","Effects of Autonomic Nervous System Modulation by Heart Rate Variability Biofeedback Training With Resonant Frequency Breathing on Glucose Metabolism in Individuals With Prediabetes","RwHRVBFinPD","Inclusion Criteria:\n\n* Presence of prediabetes Fasting glucose: 100-125 mg\u002Fdl (5.6-6.9 mmol\u002FL) and\u002For HbA1c in %: 5.7-6.4 (39-47 mmol\u002Fmol Hb) and\u002For 2-hour value of the 75 g OGTT: 140-199 mg\u002Fdl (7.8-11.0 mmol\u002FL)\n\n  * This is checked using a 75 g OGTT in a screening visit.\n* Age between 18 and 65 years\n* BMI between 20 and 40 kg\u002Fm²\n\nExclusion Criteria:\n\n* Diabetes mellitus\n* Malignant diseases within the last 5 years before randomization\n* History of gastrointestinal surgery\n* Pancreatic diseases other than pancreatic lipomatosis\n* Acute diseases or infections\n* Regular intake of cardiac drugs that affect heart rate within the last 4 weeks before the first measurement (e.g. beta-receptor blockers, antiarrhythmics, etc.)\n* Intake of centrally acting drugs\n* Medical contraindications to a meaningful interpretation of the heart rate analysis (e.g. patients with pacemakers, atrial fibrillation or other arrhythmias)\n* Chronic diseases (particularly metabolic diseases, heart diseases, blood diseases)\n* Endocrinological disease other than substituted hypothyroidism\n* Mental illnesses\n* Intake of drugs that can affect blood sugar metabolism (e.g. steroids)","65 Years",{"count":138,"type":21},60,[82],"Approximately 20% of adults have prediabetes in Germany. Prediabetes is defined as a condition with glucose levels outside the normal range but not yet meeting the criteria for type 2 diabetes. The pathogenesis of prediabetes, as well as of type 2 diabetes, involves whole-body insulin resistance associated with inadequate insulin secretion. These two central processes of glucose regulation are modulated by the brain. The brain communicates via the autonomic nervous system (ANS) with metabolically important organs in the periphery to modulate insulin sensitivity and insulin secretion. These processes are impaired in individuals with prediabetes and diabetes. An ANS sympathovagal imbalance has also been observed in individuals with prediabetes. There are no specific therapeutic approaches to improve ANS sympathovagal imbalance. It is assumed that resonant frequency breathing (RFB) maximizes heart rate variability (HRV) through rhythmization of breathing, heartbeat, and blood pressure. Through this state of coherence, the activity of the parasympathetic nervous system is upregulated, and the activity of the sympathetic nervous system is suppressed, leading to an increase in modulation of ANS activity. Several studies have demonstrated that heart rate variability-biofeedback (HRV-BF) interventions improve HRV, reduce stress and anxiety, and alleviate symptoms in patients with various medical conditions. To the best of current knowledge, no study has investigated the effect of HRV-BF-RFB on glucose metabolism. Therefore, the proposed randomized controlled non-blinded trial aims to gain evidence about the effect of HRV-BF-RFB compared to an anti-stress program on glucose metabolism in individuals with prediabetes. Glucose metabolism is characterized using the 75 g oral glucose tolerance test. There are two potential mechanisms by which HRV-BF-RFB may improve glucose metabolism in individuals with prediabetes: (a) a 0°-phase relationship between heart oscillations and breathing, maximizing the amplitude of respiratory sinus arrhythmia (RSA), and (b) activation of the cholinergic anti-inflammatory pathway. The investigators hypothesized that in individuals with prediabetes, the HRV-BF-RFB intervention will improve glucose metabolism and glucose variability.",[142],"Prediabetes",[144,145,146,147,148],"prediabetes","glucose metabolism","heart rate variability-biofeedback training","resonance frequency breathing","oral glucose tolerance test","2025-05-21",{"date":151,"type":36},"2025-05-25",{"date":153,"type":36},"2025-05-14",{"date":155,"type":21},"2027-03-31",{"name":42,"class":43},{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":16,"minAge":165,"maxAge":166,"enrollmentInfo":167,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":169,"conditions":170,"keywords":172,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":44},"100505884","fit-to-fight-childhood-cancer-100505884","NCT05867186","Fit to Fight Childhood Cancer","Fit to Fight Childhood Cancer: an Explorative Long-term Study on Exercise and Its Influence on Physical Performance and Psychosocial Aspects in Childhood Cancer Patients During and After Cancer Treatment.","Kolibri","Inclusion Criteria:\n\n* Oncological disease according to the International Classification of Childhood Cancer.\n* Planned or started anti-cancer treatment (chemo- and\u002For radiotherapy and\u002For surgery) at the Clinic and Polyclinic for Paediatrics and Adolescent Medicine of the University Medical Centre of the Johannes Gutenberg University Mainz or connection to the Paediatric Oncology Centre Mainz within the framework of aftercare.\n* The patient is assessed by the treating team (pediatric oncologist, exercise professional etc.) as suitable to participate in the trial, e.g. due to medical or psychological reasons.\n* Existing informed consent (or assent) to participate in the study.\n* The patient is not in a terminal phase of the disease.\n\nExclusion criteria:\n\n* The patient is assessed by the treating team (pediatric oncologist, exercise professional etc.) as unsuitable to participate in the trial, e.g. due to medical or psychological reasons.\n* After detailed information and, if necessary, having time to consider, the patient (≥ 16 years of age) did not agree to give written informed consent to participate in the trial. In the case of minor patients (\\\u003C16 years of age): The legal guardians do not assume that the child\u002Fadolescent is able to freely decide on participation or to consent to participation on the basis of the information received, and do not consent to this themselves.\n* The patient (and the legal guardians) has\u002Fhave insufficient knowledge of the German or English language, so that it is not possible to carry out both the informed consent and interviews (in age-appropriate language).\n* The patient is in a terminal phase of the disease.","3 Years","21 Years",{"count":168,"type":21},100,"The aim of the study is to investigate the influence of exercise on physical performance and psychosocial aspects in children and adolescents with cancer during and after treatment.",[171],"Pediatric Oncology",[173,174,175,176,177,178,179],"Paediatric exercise oncology","Precision exercise training","Childhood cancer","Quality of life","Gait","Pain","Cardiorespiratory fitness","2024-12-04",{"date":182,"type":36},"2024-12-09",{"date":184,"type":36},"2023-06-20",{"date":186,"type":21},"2029-07-31",{"name":42,"class":43},{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":194,"eligibilityCriteria":195,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":196,"enrollmentInfo":197,"targetDuration":199,"studyType":22,"phases":4,"briefSummary":200,"conditions":201,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":44},"100525719","multicenter-registry-on-microvascular-dysfunction---searching-a-new-ach-spasm-definition-100525719","NCT06125392","Multicenter Registry on Microvascular Dysfunction - Searching a New Ach Spasm Definition","A Multicenter RegIstry on the Diagnosis of Patients with Chronic Angina and No Angiographic CoRonary Artery Stenosis (international Retrospective Collection of Anonymized Patient Data) - Searching a New Ach Spasm Definition","MICRO-SNAPE","Inclusion Criteria:\n\n* Patients who underwent combined measurements of coronary pressure and flow in at least 1 native coronary artery in response to endothelium dependent and independent vasodilators.\n\nExclusion Criteria:\n\n* Hemodynamic instability\n* Age \\\u003C18 years","90 Years",{"count":198,"type":21},1000,"1 Year","The MICRO-SNAPE registry will collect data from patients undergoing investigation of microvascular dysfunction and coronary spasm in Europe and North America.",[202,203],"Coronary Microvascular Disease","Coronary Vasospasm","2024-10-30",{"date":206,"type":36},"2024-11-01",{"date":208,"type":36},"2023-09-30",{"date":210,"type":21},"2028-08-31",{"name":42,"class":43},{"id":213,"slug":214,"hasResults":11,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":218,"eligibilityCriteria":219,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":220,"targetDuration":4,"studyType":80,"phases":222,"briefSummary":223,"conditions":224,"keywords":226,"overallStatus":230,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":44},"100536826","study-comparing-two-administration-pathways-for-adenosine-during-microvascular-function-assessment-100536826","NCT06269874","Study Comparing Two Administration Pathways for Adenosine During Microvascular Function Assessment","A Single-centric, ProspectivE, Randomized Controlled Study Comparing Two Administration Pathways for Adenosine During Invasive Assessment of Microvascular Function in Patients With ANOCA.","ASPERA-ANOCA","Inclusion Criteria:\n\n* Chronic coronary syndrome (including patients with anginal equivalents).\n* Indication to cardiac catheterization;\n* Indication to the assessment of microvascular function (note: patients will be asked for participation and consented prior to the first measurement of microvascular function, which will be conducted as per clinical indication)\n* Willingness to participate and ability to understand, read and sign the informed consent\n* Age\\>18 years\n\nExclusion Criteria:\n\n* Age \\\u003C18 years\n* Bronchial asthma, COPD (chronic obstructive pulmonary disease)\n* Secondary or tertiary atrioventricular block without prior pacemaker implantation\n* Previous CABG (coronary artery bypass graft) with patent grafts to the left anterior descending coronary\n* Epicardial coronary disease (FFR \\\u003C0.80 with evidence of a focal stenosis) in the left anterior descending territory\n* Inability to provide informed consent",{"count":221,"type":21},40,[82],"The aim of this study is to investigate the agreement and reproducibility between intravenous and intracoronary adenosine administration during invasive assessment of microvascular function.\n\nGoals of this study are:\n\n1. Agreement and reproducibility between intravenous and intracoronary adenosine administration in the IMR (Index of microvascular resistance) value.\n2. Agreement and reproducibility of FFR(fractional flow reserve), CFR (coronary flow reserve), MRR (microvascular resistance reserve), RRR (resistive reserve ratio) and reproducibility of each of these as compared with CFRabs (absolute coronary flow).\n3. Time required for IMR measurements",[225],"Microvascular Coronary Artery Disease",[227,228,229],"adenosine","coronary microvascular assessment","microvascular disease","NOT_YET_RECRUITING","2024-10-06",{"date":233,"type":36},"2024-10-08",{"date":235,"type":21},"2027-03-02",{"date":237,"type":21},"2027-08-31",{"name":42,"class":43},{"id":240,"slug":241,"hasResults":11,"nctId":242,"briefTitle":243,"officialTitle":244,"acronym":245,"eligibilityCriteria":246,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":247,"targetDuration":248,"studyType":22,"phases":4,"briefSummary":249,"conditions":250,"keywords":253,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":256,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":44},"100222972","mainz-intracoronary-database-the-coronary-slow-flow-and-microvascular-diseases-registry-100222972","NCT02180178","Mainz Intracoronary Database. The Coronary Slow-flow and Microvascular Diseases Registry","Mainzer IntraCoronAry daTabase (MICAT). Das Coronary Slow Flow- Syndrom Und Koronare Mikrozirkulationsstörungen- Register.","MICAT","Inclusion Criteria:\n\n* clinical indication to coronary angiography\n\nExclusion Criteria:\n\n* none",{"count":198,"type":21},"10 Years","Primary goal of the registry is to collect prospective data on patients undergoing coronary angiography in Mainz. Following amendment of the procol, this study will also include patients who received an Aborb bioresorbable scaffold for the therapy of de novo stenoses.",[251,252],"Coronary Artery Disease","Microvascular Dysfunction",[229,254,255],"coronary artery disease","Coronary artery disease, with or without microvascular dysfuntion",{"date":233,"type":36},{"date":258,"type":4},"2013-09",{"date":260,"type":21},"2028-09",{"name":42,"class":43},{"id":263,"slug":264,"hasResults":11,"nctId":265,"briefTitle":266,"officialTitle":267,"acronym":268,"eligibilityCriteria":269,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":270,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":272,"conditions":273,"keywords":277,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":284,"lastUpdatePostDateStruct":285,"startDateStruct":287,"completionDateStruct":289,"leadSponsor":291,"locationsCount":44},"100221153","vteval-project---prospective-cohort-studies-to-evaluate-and-improve-diagnostics-management-strategies-and-risk-stratification-in-vte-100221153","NCT02156401","VTEval Project - Prospective Cohort Studies to Evaluate and Improve Diagnostics, Management Strategies and Risk Stratification in VTE","VTEval Project - Three Observational, Prospective Cohort Studies Including Biobanking to Evaluate and Improve Diagnostics, Management Strategies and Risk Stratification in Venous Thromboembolism","VTEval","Inclusion Criteria:\n\n* Age ≥18 years and Informed written consent\n* Clinical condition:\n\n  * Cohort 1: Clinical suspicion of acute PE (with or without DVT)\n  * Cohort 2: Clinical suspicion of acute DVT (without symptomatic PE)\n  * Cohort 3: Incidentally diagnosed VTE",{"count":271,"type":21},2000,"Venous thromboembolism (VTE) with its two clinical manifestations deep vein thrombosis (DVT) and pulmonary embolism (PE) is a life-threatening disease that is associated with considerable morbidity and mortality. The incidence of VTE increases with age and it - as the third most common cardiovascular disease after ischemic heart disease and stroke - represents an important public health problem in industrialized countries with several aspects in need to be addressed.\n\nVTEval Project includes three long-term prospective observational studies to evaluate and improve VTE diagnostics and management, treatment and outcome. The aims of the project include a systematic assessment of VTE, i.e. disease status (symptoms, clinical and subclinical aspects) and risk profiles (classic, psychosocial and environmental factors), using a system-oriented approach. VTEval collects three large prospective cohorts of patients with suspected and incident VTE consisting of individuals with a clinical suspicion of acute PE, individuals with a clinical suspicion of acute DVT, and individuals with incidental diagnosis of VTE).\n\nThe standardized and harmonized data acquisition of the study establishes a sustainable resource for comprehensive research on VTE, thus providing the basis for both short- and long-term analysis.",[274,275,276],"Venous Thromboembolism (VTE)","Deep Vein Thrombosis (DVT)","Pulmonary Embolism (PE)",[278,279,280,281,282,283],"Venous thromboembolism","Deep vein thrombosis","Pulmonary embolism","Cohort study\u002Fepidemiology","Outcome","Prognosis","2024-06-14",{"date":286,"type":36},"2024-06-17",{"date":288,"type":36},"2013-04",{"date":290,"type":21},"2030-07",{"name":42,"class":43},{"id":293,"slug":294,"hasResults":11,"nctId":295,"briefTitle":296,"officialTitle":296,"acronym":297,"eligibilityCriteria":298,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":299,"enrollmentInfo":300,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":302,"conditions":303,"keywords":4,"overallStatus":230,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":306,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":44},"100463296","evaluating-the-diagnostic-and-predictive-value-of-non-invasive-tests-nits-on-the-progression-of-chronic-liver-disease-100463296","NCT05312853","Evaluating the Diagnostic and Predictive Value of Non-invasive Tests (NITs) on the Progression of Chronic Liver Disease.","NITOutcomes","Inclusion Criteria:\n\n1. Age ≥18 years\n2. Clinically suspected chronic liver disease based on any of:\n\n   1. Patient with historical liver biopsy providing histological evidence of any liver disease or,\n   2. Patient undergoing liver biopsy for suspected chronic liver disease with biochemical and\u002For radiological findings consistent with liver disease or,\n   3. Patient with clinical and radiological evidence of cirrhosis (in absence of an alternative aetiology)\n   4. Patients with metabolic risk factors predisposing to CLD\n\nExclusion Criteria:\n\n1. Refusal or inability (lack of capacity) to give informed consent.\n2. Age \\\u003C 18 years\n3. Pregnancy\n4. An active malignancy.\n5. Life expectation of \\\u003C 5 years.\n6. Patients not meeting inclusion criteria or judged by the investigator to be unsuitable for inclusion in the study.","99 Years",{"count":301,"type":21},250,"Primary objective is to study the relevance of non-invasive test (NITs) in predicting disease stage (diagnostic biomarker) and outcome (predictive biomarker) in patients with suspected or established liver disease and cirrhosis.",[304],"Chronic Liver Disease","2023-12-27",{"date":307,"type":36},"2024-01-03",{"date":309,"type":21},"2024-01-15",{"date":311,"type":21},"2034-12-31",{"name":42,"class":43},{"id":314,"slug":315,"hasResults":11,"nctId":316,"briefTitle":317,"officialTitle":318,"acronym":319,"eligibilityCriteria":320,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":111,"enrollmentInfo":321,"targetDuration":4,"studyType":80,"phases":323,"briefSummary":324,"conditions":325,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":327,"lastUpdatePostDateStruct":328,"startDateStruct":330,"completionDateStruct":332,"leadSponsor":334,"locationsCount":44},"100409051","cosima-coronary-sinus-reducer-for-the-treatment-of-refractory-microvascular-angina-100409051","NCT04606459","COSIMA: COronary SInus Reducer for the Treatment of Refractory Microvascular Angina","A Multicentric Randomized Open Label Controlled Superiority Trial to Evaluate the Effectiveness of a Therapy With a Coronary Sinus Reducer as Compared to Guideline-directed Medical Therapy in Patients With Refractory Microvascular Angina","COSIMA","Inclusion Criteria:\n\n* Age ≥ 18 and ≤85 years\n* Chronic coronary syndrome (including patients with anginal equivalents) refractory angina CCS class III-IV despite guideline-directed medical therapy\n* Evidence of reversible ischemia on non-invasive testing\n* Evidence of microvascular disease as diagnosed invasively by at least one of the following:\n\n  1. index of microvascular resistances (IMR) \\>25 and\u002For\n  2. coronary flow reserve (CFR) \\\u003C2.0) with fractional flow reserve (FFR)\\>0.8.\n* Willingness to participate and ability to understand, read and sign the informed consent document before enrollment in the trial.\n\nExclusion Criteria:\n\nSubjects presenting at least one of the following criteria will not be enrolled in the trial\n\n* Recent (within 3 months) acute coronary syndrome\n* Recent (within 6 months) revascularization by percutaneous coronary intervention (PCI, stent) or coronary artery by-pass surgery (CABG)\n* Recent (within 30 days) unsuccessful PCI\n* Decompensated congestive heart failure (CHF) or hospitalization due to CHF during the last 3 months\n* Left ventricular ejection fraction of \\\u003C30%\n* Mean right atrial pressure \\>15mmHg\n* Anomalous or abnormal CS anatomy (e.g., tortuosity, aberrant branch, persistent left superior vena cava \\[SVC\\]) as demonstrated by angiogram\n* CS diameter at the site of planned Reducer implantation greater than 13mm or less than 9.5mm as measured by angiogram\n* Severe chronic obstructive pulmonary disease (COPD) indicated by a forced expiratory volume in one second that is less than 55 percent of the predicted value\n* Severe valvular heart disease\n* A pacemaker electrode in the coronary sinus\n* Tricuspid valve replacement or repair\n* Chronic renal failure (serum creatinine \\>2mg\u002FdL), and\u002For on chronic hemodialysis\n* Moribund, or with comorbidities limiting life expectancy to less than one year\n* Known severe reaction to required procedural medications\n* Known allergy to stainless steel or nickel\n* Need for Magnetic Resonance Imaging (MRI) within 8 weeks after reducer implantation\n* Contraindication to dual antiplatelet therapy\n* Female of childbearing potential (last menstruation within the last 12 months or who did not undergo tubal ligation, ovariectomy or hysterectomy)",{"count":322,"type":21},144,[82],"Patients with refractory microvascular angina fulfilling the predefined inclusion and exclusion criteria will be enrolled in this randomized trial. The primary objective is to investigate whether the proportion of patients reporting an improvement in Canadian Cardiovascular Society (CCS) angina class (≥2 classes) is different at six months after implantation of a Coronary Sinus Reducer followed by optimal medical therapy (OMT) compared to OMT alone.",[202,326],"Refractory Angina","2023-09-26",{"date":329,"type":36},"2023-09-28",{"date":331,"type":36},"2021-04-01",{"date":333,"type":21},"2029-10-20",{"name":42,"class":43},{"id":336,"slug":337,"hasResults":11,"nctId":338,"briefTitle":339,"officialTitle":340,"acronym":341,"eligibilityCriteria":342,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":343,"enrollmentInfo":344,"targetDuration":165,"studyType":22,"phases":4,"briefSummary":346,"conditions":347,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":357,"lastUpdatePostDateStruct":358,"startDateStruct":360,"completionDateStruct":362,"leadSponsor":364,"locationsCount":44},"100463950","mainz-register-of-patients-with-sleep-disorders-100463950","NCT05321355","Mainz Register of Patients With Sleep Disorders","Study on Disease Course and Quality of Life in Patients With Sleep Disorders (Mainz Sleep Registry)","MAINZ-SLEEPREG","Inclusion Criteria:\n\n* patients with narcolepsy\n* patients with other neurological sleep disorders\n\nExclusion Criteria:\n\n* patients aged \\\u003C18 years\n* patients who cannot provide informed consent and don't have a legal guardian","120 Years",{"count":345,"type":21},500,"Prospective longitudinal observational registry study of all patients with sleep disorders treated in the Mainz Comprehensive Epilepsy and Sleep Medicine Center with the focus on the course of the disease and quality of life.",[348,349,350,351,352,353,354,355,356],"Sleep Disorder","Sleep Disorder Parasomnia","Narcolepsy","Sleep Apnea","Insomnia","Somnambulism","Idiopathic Hypersomnia","Restless Legs Syndrome","REM Behavior Disorder","2022-09-11",{"date":359,"type":36},"2022-09-15",{"date":361,"type":36},"2022-02-01",{"date":363,"type":21},"2030-01-31",{"name":42,"class":43},{"id":366,"slug":367,"hasResults":11,"nctId":368,"briefTitle":369,"officialTitle":370,"acronym":371,"eligibilityCriteria":372,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":111,"enrollmentInfo":373,"targetDuration":374,"studyType":22,"phases":4,"briefSummary":375,"conditions":376,"keywords":378,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":381,"lastUpdatePostDateStruct":382,"startDateStruct":384,"completionDateStruct":386,"leadSponsor":388,"locationsCount":44},"100409502","micro-a-registry-study-in-patients-with-microvascular-angina-100409502","NCT04612322","MICRO: a Registry Study in Patients With Microvascular Angina","A Multicenter Registry on the Diagnosis of Patients With Chronic Angina and no Angiographic Coronary Artery Stenosis","MICRO","Inclusion Criteria:\n\n* Age ≥ 18 and \\\u003C85 years.\n* Chronic coronary syndrome (including patients with anginal equivalents)\n* Angina CCS class II-IV\n* Evidence of reversible ischemia on non-invasive testing\n* Availability of the following measurements:\n\n  1. Index of microvascular resistances (IMR),\n  2. Resting full-cycle ratio (RFR),\n  3. Fractional flow reserve (FFR),\n  4. Coronary flow reserve (CFR)\n* Willingness to participate and ability to understand read and signed the informed consent document before the procedure\n\nExclusion Criteria:\n\nAt least one of the following:\n\n* Pregnancy and or lactation.\n* Medical or psychological conditions that would jeopardize an adequate and orderly participation.\n* Left ventricular ejection fraction lower than 30%\n* Previous coronary artery bypass surgery (CABG) to all major branches in the LAD and left circumflex (LCX) territory, such that IMR cannot be measured\n* Decompensated congestive heart failure (CHF)\n* Chronic or acute renal failure with creatinine \\>2mg\u002Fdl\n* Severe valvular heart disease\n* Patients with comorbidities limiting life expectancy to less than one year",{"count":198,"type":21},"5 Years","The evidence above demonstrates that microvascular dysfunction is an important determinant of patient prognosis, which however remains poorly classified. Given the high burden of disease and the severity of the functional impairment in these patients, the lack of a clear definition for this disease has a potentially large clinical importance. It is important to better describe the phenotype of these patients, identify the predictors of prognosis, and determine the impact of diagnosis.",[377],"Microvascular Disease",[379,380],"Coronary artery disease","Angina","2022-03-29",{"date":383,"type":36},"2022-03-31",{"date":385,"type":36},"2020-10-10",{"date":387,"type":21},"2029-10-10",{"name":42,"class":43},""]